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Abstract 
Several reproductive factors are known to be associated with risk of breast cancer; however, relationships between 
these factors with risk of second primary asynchronous contralateral breast cancer (CBC) have not been widely stud-
ied. The Women’s Environmental, Cancer, and Radiation Epidemiology (WECARE) Study is a population-based case-
control study of 1521 CBC cases and 2212 individually matched controls with unilateral breast cancer. Using multivari-
able conditional logistic regression models, we examined associations between reproductive factors and CBC risk, 
and whether associations differed by estrogen receptor (ER) status and menopausal status of the first breast cancer. 
Older age at menarche was inversely associated with CBC risk (≥14 vs. ≤11 years risk ratio (RR) = 0.82, 95 % confi-
dence interval (CI) 0.65–1.03, Ptrend = 0.02). Among parous women, an increasing number of full-term pregnancies 
(FTP) was inversely associated with risk (≥4 vs. 1 FTP RR = 0.60, 95 % CI 0.41–0.88, Ptrend = 0.005). Ever breast-feeding 
was inversely associated with CBC risk only among women with ER-negative first tumors (ever vs. never breast-fed 
RR = 0.69, 95 % CI 0.48–1.00, Pheterogeneity = 0.05). Older age at first FTP was inversely associated with CBC risk among 
women with ER-negative first tumors (≥30 vs. <20 years old RR = 0.66, 95 % CI 0.35–1.27, Ptrend = 0.03), but sugges-
tively positively associated with risk among women with ER-positive first tumors (Pheterogeneity = 0.03). Young age at 
menarche and low parity, both risk factors for first primary breast cancer, were also associated with overall CBC risk. 
Reductions in risk associated with breast-feeding were limited to women with ER-negative first tumors, who are at 
higher CBC risk than women with ER-positive primaries.
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Background
Reproductive factors, including menstrual and repro-
ductive history, are well-established predictors of breast 
cancer risk. Young age at menarche and late age at men-
opause, representing an increased number of lifetime 
menstrual cycles, are associated with increased risk (Col-
laborative Group on Hormonal Factors in Breast Cancer 
2012). Parity is associated with decreased risk, though 
a protective effect is observed only among women with 
young ages at first birth; women with a first birth occur-
ring after age 35  years tend to be at a higher lifetime 
risk relative to nulliparous women (Rosner et  al. 1994; 
Trichopoulos et  al. 1983). Substantial evidence sug-
gests that associations between reproductive factors and 
breast cancer vary by tumor subtypes defined by hor-
mone receptor status and molecular subtype (Anderson 
et al. 2014). For example, inverse associations with young 
age at first birth and higher parity are stronger for estro-
gen receptor-positive (ER-positive) compared to estro-
gen receptor-negative (ER-negative) tumors (Althuis 
et  al. 2004; Ma et  al. 2006; Ritte et  al. 2013; Yang et  al. 
2011). Conversely, the protective effect of breast-feeding 
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appears to be stronger for, or limited to, ER-negative 
subtypes (Ma et al. 2006; Ambrosone et al. 2014; Gaudet 
et  al. 2011; Li et  al. 2013; Millikan et  al. 2008; Tamimi 
et al. 2012).
Among women diagnosed with breast cancer, the 
risk of developing a second primary asynchronous con-
tralateral breast cancer (CBC) is greater than the risk of 
developing a primary breast cancer in the general popu-
lation (Curtis RE et  al. 1973). First and second primary 
breast tumors have been shown to share some risk fac-
tors, including mutations in BRCA1 and BRCA2 (Graeser 
et al. 2009; Metcalfe et al. 2004), family history of breast 
cancer (Bernstein et  al. 1992; Hemminki et  al. 2007), 
and obesity (Druesne-Pecollo et  al. 2012). Reproduc-
tive factors have been implicated in the etiology of CBC, 
though associations have been less consistent than those 
observed for first primary breast cancers. In the first 
phase of the Women’s Environmental, Cancer, and Radia-
tion (WECARE) Study, a population-based case-control 
study of cases with CBC and controls with unilateral 
breast cancer (UBC), we observed an inverse association 
between number of full-term pregnancies and CBC risk, 
and a positive association with young age at menarche 
(Largent et  al. 2007). Some prior studies have simi-
larly observed a reduced risk of CBC with parity (Bern-
stein et  al. 1992; Ricceri et  al. 2015; Storm et  al. 1992) 
and younger age at first birth (Vaittinen and Hemminki 
2000), though others, potentially limited by small sam-
ple sizes, have reported null associations with these and 
other reproductive factors (Boice et al. 1992; Cook et al. 
1996; Horn and Thompson 1988; Li et al. 2003). To date, 
no studies of CBC have investigated whether these asso-
ciations are modified by estrogen receptor (ER) status.
In the present study, we sought to clarify the associa-
tions between reproductive factors and CBC risk in the 
WECARE Study population, which recently completed 
its second phase. In addition to the 708 matched case-
control triplets included in our previous analysis (Largent 
et  al. 2007), the current analysis includes an additional 
813 matched case-control pairs, giving us substantially 
increased power to examine these relationships. Our 
large and expanded sample size enabled us to examine 
potential heterogeneity by ER status and menopausal sta-
tus of the first primary tumor.
Methods
Study population
The WECARE Study is a multicenter, population-
based case-control study of cases with asynchronous 
CBC and individually matched controls with UBC. The 
study design of the first phase (WECARE I) has been 
described in detail elsewhere (Bernstein et al. 2004); the 
second phase (WECARE II) employed a nearly identical 
approach [Langballe et  al, submitted]. Briefly, partici-
pants in each phase were identified through eight popu-
lation-based cancer registries, including six in the United 
States that contribute to the National Cancer Institute’s 
Surveillance, Epidemiology, and End Results (SEER) pro-
gram: Los Angeles County Cancer Surveillance Program; 
Cancer Surveillance System of the Fred Hutchinson Can-
cer Research Center (Seattle region, WA); State Health 
Registry of Iowa; Cancer Surveillance Program of Orange 
County/San Diego-Imperial Organization for Cancer 
Control (Orange County/San Diego, CA); the Greater 
Bay Area Cancer Registry (San Francisco Bay Area region 
and Santa Clara region, CA); and the Sacramento and 
Sierra Center Registry (Sacramento region, CA). Par-
ticipants were additionally identified using the Ontario 
Cancer Registry (Canada) and the Danish Breast Can-
cer Cooperative Group Registry, supplemented by data 
from the Danish Cancer Registry. The study protocol was 
approved by the institutional review boards at each study 
site and by the Ethics Committee System in Denmark.
Eligible cases were women who: (1) were diagnosed 
between 1985 and 2009 with a first invasive breast cancer 
that did not spread beyond regional lymph nodes at diag-
nosis and a second contralateral primary breast cancer at 
least 1 year after the first breast cancer diagnosis (refer-
ence date); (2) were younger than 55 years at first diagno-
sis; (3) had no previous or intervening cancer diagnosis 
except non-melanoma skin cancer or cervical carcinoma 
in  situ; (4) were alive at the time of contact and able to 
provide informed consent to complete the interview and 
provide a biospecimen; and (5) resided in the same can-
cer registry reporting region for both diagnoses. Eligible 
controls with an intact contralateral breast were identi-
fied using the same eligibility criteria, and individually 
matched to cases (1:2 in WECARE I; 1:1 in WECARE II) 
on the following criteria: year of birth (5-year strata), year 
of diagnosis (4-year strata), cancer registry region, and 
race/ethnicity. For each control, reference date was cre-
ated by adding the at-risk period of her matched case to 
the date of her breast cancer diagnosis. WECARE I cases 
and controls were counter-matched on radiation expo-
sure, such that two members of the case-control triad 
had received radiation therapy for their first breast can-
cer. In total, 2354 CBC cases and 3599 UBC controls met 
eligibility criteria and were approached for inclusion in 
the study. Of those eligible women, 1521 cases (64.6  %) 
and 2212 (61.5 %) controls completed the interview, pro-
vided a biospecimen (blood or saliva), and provided writ-
ten informed consent.
Data collection
Study participants were interviewed by telephone using 
a structured questionnaire aimed at evaluating known or 
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suspected breast cancer risk factors, including personal 
demographics, medical history, menstrual and reproduc-
tive history, family history of cancer, use of hormones, 
smoking, and alcohol intake. Risk factor status was 
assessed during the period prior to first diagnosis, as well 
as between first diagnosis and reference date (i.e., the at-
risk period for CBC). Reproductive risk factors that were 
assessed included: age at menarche, number of pregnan-
cies, duration and outcome of each pregnancy, date each 
pregnancy ended, duration of breast-feeding for each live 
birth, menopausal status, age at menopause and reason 
for menopause. A full-term pregnancy (FTP) was defined 
as a pregnancy that resulted in a stillbirth or at least one 
live birth. Breast-feeding duration was calculated by sum-
ming months of breast-feeding duration for each live 
birth. Detailed data on treatment and tumor characteris-
tics, including ER and progesterone receptor (PR) status, 
were obtained directly from cancer registry records or 
by abstracting medical records, including pathology and 
surgical reports, radiation oncology clinic notes, and sys-
temic adjuvant treatment data. Self-reported treatment 
data were used for participants with missing information 
in their medical records (chemotherapy, 4  %; hormonal 
therapy, 5 %).
Statistical analysis
Multivariable-adjusted risk ratios (RRs) and correspond-
ing 95  % confidence intervals (CIs) were estimated by 
fitting conditional logistic regression models to the 
combined WECARE I and WECARE II data. We evalu-
ated the following reproductive risk factors among all 
women: age at menarche (≤11, 12, 13, ≥14  years), par-
ity (parous vs. nulliparous), menopausal status (2  years 
prior to first breast cancer diagnosis) and age at meno-
pause (premenopausal, postmenopausal/≤45  years, 
postmenopausal/>45  years). In order to reduce the 
potential misclassification of menopausal status due to 
treatment-induced menstrual irregularities, we consid-
ered women premenopausal at first diagnosis if they 
reported menstruating or being pregnant in the 2  years 
before diagnosis. We examined number of FTP (1, 2, 
3, ≥4), age at first FTP (< 20, 20–24, 25–29, ≥30 years), 
time between menarche and first FTP (<10, 10–14, 
15–19, ≥20 years), time since last FTP (<5, 5 to <10, 10 
to <15, 15 to <20,  ≥20  years) and duration of breast-
feeding (never, ≤6, 7–12, 13–24, ≥25 months). We also 
evaluated whether time since last birth was associated 
with CBC risk, using the method outlined by Heuch 
et al. (1999) to avoid linear dependence between attained 
age, age at birth and time since birth among uniparous 
women. Briefly, nulliparous women were assigned to the 
referent categories for age at first FTP and time since last 
FTP and included in models with parous women; effects 
were estimated among parous women only by adding an 
indicator for parity (yes, no) to the model. Multivariable 
models were adjusted for the following known and sus-
pected CBC risk factors: age at first breast cancer diag-
nosis (continuous), first-degree family history of breast 
cancer (yes, no, adopted/unknown), lobular histology 
of first breast cancer (yes, no, unknown), and receipt of 
hormonal treatment (yes, no, unknown), radiation ther-
apy (yes, no, unknown) and/or chemotherapy (yes, no, 
unknown) for first diagnosis. Further adjustment for type 
of chemotherapy (i.e., taxanes, anthracycline-based regi-
mens, cyclophosphamide with methotrexate and fluoro-
uracil, or other chemotherapeutics) did not appreciably 
change results, and this covariate was not retained in 
final models. Models were additionally mutually adjusted 
for the reproductive factors of interest, with the excep-
tion of time since last FTP, which we hypothesized may 
lie on the causal pathway between pregnancy-related var-
iables and CBC risk.
Time-varying reproductive factors, including number 
and age at FTP and breast-feeding, were evaluated at 
the time of first diagnosis as well as at the reference date. 
Analyses produced similar results and, with the excep-
tion of menopausal status, estimates are shown for repro-
ductive variables as of the reference date.
In additional analyses, we examined whether asso-
ciations between reproductive factors and CBC risk dif-
fered according to ER status of the first primary tumor, 
menopausal status at first diagnosis, and time since first 
diagnosis. Because PR status was unknown for approxi-
mately 25 % of first primary tumors, we did not examine 
whether associations differed by joint ER and PR status. 
However, among tumors with data on both markers, 
approximately 90 % of ER-positive first tumors were also 
PR-positive; similarly, about 90  % of ER-negative first 
tumors were also PR-negative. Likelihood ratio tests were 
used to assess heterogeneity by potential effect modifiers. 
Analyses were conducted using SAS v. 9.4 (SAS Institute, 
Cary, NC).
Results
Characteristics of the 1521 CBC cases and 2212 UBC 
controls included in our analysis are shown in Table  1. 
Median age at first diagnosis was 46 years; among cases, 
the median time to CBC diagnosis was 6.3  years. Data 
on ER status of the first primary tumor were available for 
approximately 83 % of participants (83 % for cases, 82 % 
for controls); among women with available ER status, 
67 % had ER-positive first tumors. Approximately 80 % of 
participants reported at least one FTP at the time of first 
diagnosis, with a median age at first FTP of 24 years.
Women who reported age at menarche of 14 years or 
older had an 18 % lower risk of CBC compared to those 
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who had their first menses at age 11  years or younger 
(RR =  0.82, 95 % CI 0.65–1.03, Ptrend =  0.02) (Table 2). 
Women with at least one FTP at the time of first diagno-
sis were not at a reduced risk of CBC compared to nul-
liparous women, and a pregnancy occurring after first 
diagnosis was not associated with risk. Among parous 
women, increasing parity was inversely associated 
with risk (≥4 vs. 1 FTP RR =  0.60, 95  % CI 0.41–0.88, 
Ptrend  =  0.005) but there was no clear trend between 
increasing age at first FTP and CBC risk (Ptrend = 0.82). 
A long interval between menarche and first FTP was 
suggestively associated with increased CBC risk, though 
no statistically significant trend was observed (≥20 
vs.  <10  year interval RR  =  1.33, 95  % CI 0.94–1.88, 
Ptrend  =  0.12). No clear trends between CBC risk and 
either breast-feeding duration or time since last birth 
were observed among parous women. Lastly, menopausal 
status at first diagnosis was not associated with CBC risk.
Table  3 shows RRs for the associations of reproduc-
tive factors with CBC risk stratified by ER status of the 
first primary tumor. Among parous women, a history 
of breast-feeding was associated with a reduced risk 
of CBC risk only among women with ER-negative first 
tumors (ever breast-fed ER-negative vs. never breastfed 
RR = 0.69, 95 % CI 0.48–1.00 vs. ER-positive RR = 1.09, 
95  % CI 1.09, 95  % CI 0.81, 1.47, Pheterogeneity  =  0.05). 
Although there was no statistically significant trend 
observed with increasing duration, women with ER-neg-
ative tumors who had breast-fed for 25 months or longer 
had the greatest reduction in CBC risk relative to those 
who had never breast-fed (RR = 0.48, 95 % CI 0.22, 1.02, 
Ptrend =  0.15). High parity was associated with reduced 
CBC risk regardless of ER status of the first tumor 
(Pheterogeneity  =  0.95). Older age at FTP was associated 
with a lower risk of CBC among women with ER-neg-
ative first tumors, while a statistically non-significant 
positive association was observed among those with 
ER-positive disease (age at FTP  ≥30 vs.  <20  years ER-
positive RR = 1.43, 95 % CI 0.87–2.36, Ptrend = 0.18 vs. 
ER-negative RR = 0.66, 95 % CI 0.35–1.27, Ptrend = 0.03; 
Pheterogeneity  =  0.03). No statistically significant 
Table 1 Characteristics of  contralateral breast cancer 
(CBC) cases and  unilateral breast cancer (UBC) controls 
from the WECARE Study population




Median Range Median Range
Age at first diagnosis (years) 46 24–55 46 23–55
Age at reference date (years) 53 27–73 52 27–71
Length of at-risk period (years)a 6.3 1.0–19.8 5.5 1.0–19.8
N (%) N (%)
Study center
 Iowa 201 (13) 314 (14)
 California sites 658 (43) 967 (44)
 Seattle 224 (15) 317 (14)
 Denmark 279 (18) 457 (21)
 Ontario 159 (10) 157 (7)
Year of diagnosis
 1985–1988 238 (16) 467 (21)
 1989–1992 415 (27) 647 (29)
 1993–1996 427 (28) 632 (29)
 1997–2008 441 (29) 466 (21)
First degree family history of breast cancer
 No 1004 (66) 1706 (77)
 Yes 497 (33) 466 (21)
 Adopted/unknown 20 (1) 40 (2)
Histology of first diagnosis
 Lobular 179 (12) 223 (10)
 Other 1338 (88) 1986 (90)
 Unknown 4 (0) 3 (0)
Stage of first diagnosis
 Local 1061 (70) 1442 (65)
 Regional 448 (29) 759 (34)
 Unknown 12 (1) 11 (1)
Estrogen receptor (ER) status of first diagnosisb
 Positive 797 (52) 1254 (57)
 Negative 467 (31) 561 (25)
 Other 257 (17) 397 (18)
Progesterone receptor (PR) status of first diagnosisb
 Positive 687 (45) 1083 (49)
 Negative 442 (29) 549 (25)
 Other 392 (26) 580 (26)
Chemotherapy
 No 699 (46) 923 (42)
 Yes 822 (54) 1289 (58)
Radiation treatment
 No 641 (42) 525 (24)
 Yes 880 (58) 1686 (76)
 Unknown 0 (0) 1 (0)
Hormone treatment
 No 964 (63) 1270 (57)
 Yes 557 (37) 940 (43)
Table 1 continued




Median Range Median Range
 Unknown 0 (0) 2 (0)
a Beginning at least 1 year after first diagnosis extending to the reference date 
(date of second diagnosis in cases)
b Refers to receptor status of the first primary breast cancer. The ‘Other’ category 
consists of women where no lab test was given, the test was given and the 
results are unknown or the test was given and the results were borderline
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Table 2 Age- and  multivariable-adjusted risk ratios (RR) and  95  % confidence intervals (95  % CI) for  associations 









Age at menarche (years)
 ≤11 305 (20) 437 (20) 1.0 (ref.) 1.0 (ref.)
 12 419 (28) 528 (24) 1.16 (0.93, 1.44) 1.16 (0.93, 1.44)
 13 404 (27) 589 (27) 0.95 (0.77, 1.18) 0.96 (0.77, 1.19)
 ≥14 387 (25) 650 (29) 0.81 (0.65, 1.01) 0.82 (0.65, 1.03)
 Pdtrend 0.009 0.02
Full-term pregnancies at first diagnosis
 None 311 (20) 399 (18) 1.0 (ref.) 1.0 (ref.)
 ≥1 1208 (79) 1810 (82) 0.91 (0.76, 1.08) 0.92 (0.77, 1.11)
Full-term pregnancies between first diagnosis and reference date
 Parous at first diagnosis, no interval pregnancy 1189 (78) 1785 (81) 1.0 (ref.) 1.0 (ref.)
 Nulliparous at reference date 311 (20) 399 (18) 1.11 (0.93, 1.33) 0.96 (0.76, 1.21)
 Full-term pregnancy between first diagnosis and refer-
ence date
19 (1) 25 (1) 1.30 (0.63, 2.66) 0.96 (0.76, 1.21)
Number of full-term pregnancies at first diagnosisc
 1 264 (22) 341 (19) 1.0 (ref.) 1.0 (ref.)
 2 572 (47) 847 (47) 0.93 (0.74, 1.19) 0.97 (0.75, 1.25)
 3 260 (22) 390 (22) 0.80 (0.61, 1.05) 0.87 (0.65, 1.17)
 ≥4 112 (9) 232 (13) 0.57 (0.41, 0.81) 0.60 (0.41, 0.88)
 Pdtrend 0.001 0.005
Age at first full-term pregnancy at reference date (years)c
 <20 175 (14) 276 (15) 1.0 (ref.) 1.0 (ref.)
 20–24 444 (37) 667 (37) 1.26 (0.97, 1.65) 1.19 (0.90, 1.58)
 25–29 355 (29) 550 (30) 1.10 (0.83, 1.45) 1.01 (0.75, 1.35)
 ≥30 234 (19) 317 (18) 1.36 (0.99, 1.86) 1.20 (0.84, 1.70)
 Pdtrend 0.25 0.82
Breastfeeding at reference date (months)c
 Never 680 (45) 940 (43) 1.0 (ref.) 1.0 (ref.)
 Ever 837 (55) 1268 (57) 0.86 (0.75, 1.00) 0.84 (0.69, 1.02)
 ≤6 430 (28) 643 (29) 0.91 (0.77, 1.08) 0.88 (0.71, 1.09)
 7–12 185 (12) 270 (12) 0.94 (0.74, 1.19) 0.91 (0.69, 1.19)
 13–24 141 (9) 232 (10) 0.74 (0.58, 0.95) 0.72 (0.54, 0.96)
 ≥25 81 (5) 123 (6) 0.78 (0.56, 1.07) 0.77 (0.55, 1.10)
 Pdtrend 0.02 0.06
Time since last full-term pregnancy, at reference date (years)c
 <5 37 (3) 50 (3) 1.12 (0.66, 1.90) 1.19 (0.66, 2.14)
 5–<10 57 (5) 122 (7) 0.61 (0.41, 0.93) 0.63 (0.40, 1.01)
 10 –<15 129 (11) 195 (11) 0.89 (0.65, 1.20) 0.93 (0.66, 1.31)
 15–<20 203 (17) 305 (17) 0.96 (0.76, 1.21) 0.99 (0.76, 1.29)
 ≥20 782 (65) 1138 (63) 1.0 (ref.) 1.0 (ref.)
 Pdtrend 0.26 0.49
Time between menarche and first full-term pregnancy at reference date (years)c
 <10 407 (34) 649 (36) 1.0 (ref.) 1.0 (ref.)
 10–14 422 (35) 637 (35) 1.16 (0.94, 1.43) 1.20 (0.96, 1.49)
 15–19 239 (20) 346 (19) 1.12 (0.87, 1.45) 1.10 (0.83, 1.44)
 ≥20 136 (11) 170 (9) 1.35 (0.97, 1.87) 1.33 (0.94, 1.88)
 Pdtrend 0.07 0.12
Menopausal status/age at menopause at 2 years before first diagnosis
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heterogeneity by ER status was observed for the time 
between menarche and first FTP; however, results 
indicate modest heterogeneity for longer intervals 
between menarche and FTP with risk increasing among 
women with ER-positive first tumors and risk decreas-
ing among those with an ER-negative first tumor 
(Pheterogeneity = 0.10).
Results of analyses jointly stratified analyses by ER 
status of first tumor and menopausal status 2  years 
prior to first diagnosis are shown in Table  4. Older age 
at menarche was associated with reduced risk only 
among women who were postmenopausal at first diag-
nosis (≥14 vs. ≤11 years RR = 0.45, 95 % CI 0.25–0.81, 
Ptrend  <  0.001, Pheterogeneity  =  0.0001), with similar RR 
estimates irrespective of ER status (Table  4). A history 
of breast-feeding was associated with reduced risk only 
among premenopausal women diagnosed with an ER-
negative first tumor (Pheterogeneity  =  0.07). Though tests 
of heterogeneity were not statistically significant, a long 
interval between menarche and first FTP was associated 
with an increased risk of CBC only among postmenopau-
sal women who were diagnosed with an ER-positive first 
tumor (Ptrend  =  0.009), whereas among premenopausal 
women diagnosed with an ER-negative first tumor, a long 
interval was associated with reduced risk (Ptrend = 0.05).
Discussion
Results from our large, population-based case-con-
trol study indicate that age at menarche and parity are 
related to CBC risk. Consistent with our findings from 
the first phase of the WECARE Study (Largent et  al. 
2007), we observed inverse associations of increasing 
age at menarche and higher parity with CBC risk in our 
expanded study population. Additionally, the risk varied 
by ER status of the first primary tumor and menopausal 
status at first diagnosis, suggesting etiologic differences 
across tumor subtype. For example, breast-feeding was 
associated with a reduced CBC risk only among women 
with ER-negative tumors and was limited to women 
who were premenopausal at first diagnosis. The inverse 
association between age at menarche and CBC risk was 
observed only among women who were postmenopausal 
at first diagnosis, regardless of ER status of the first can-
cer. Long interval between menarche and first FTP was 
positively associated with CBC risk only among post-
menopausal women with an ER-positive first tumor.
Previous studies of reproductive factors and CBC risk have 
produced somewhat inconsistent results, and many were 
limited by small sample sizes and limited covariate data. 
Excepting our prior analysis (Largent et al. 2007), studies of 
U.S. women have included fewer than 400 CBC cases each 
(Bernstein et  al. 1992; Boice et  al. 1992; Cook et  al. 1996; 
Horn and Thompson 1988; Li et al. 2003). Studies conducted 
within European cancer registries have had larger sample 
sizes. The largest to date had 2529 CBC cases with limited 
reproductive data identified in the Swedish Family-Cancer 
Database (Vaittinen and Hemminki 2000), and reported 
modest inverse associations for both parity and age at first 
birth with CBC risk; however, no other reproductive risk fac-
tors were examined in this study. Most recently, in an analy-
sis including 121 CBC cases in the European Investigation 
into Cancer and Nutrition (EPIC) Study, Ricceri et al. (2015) 
reported a 42 % reduced risk of CBC for parous relative to 
nulliparous women; however, data on important covariates, 
including mastectomy, were not available.
Our data suggest that the importance of early hormo-
nal and cellular changes mediated through reproductive 
events persists across multiple cancer events. Following 
a first FTP, risk of developing breast cancer is elevated; 
however, risk decreases over time, leading to a net pro-
tective influence of pregnancy on lifetime risk for women 
with younger ages at first FTP relative to nulliparous 
women (Rosner et  al. 1994; Trichopoulos et  al. 1983; 
Albrektsen et  al. 2005; Hsieh et  al. 1994; Lambe et  al. 
1994). The protective effect of parity on breast cancer risk 
may be mediated through pregnancy-induced differentia-
tion of mammary stem cells, which reduces the popula-
tion of cells at risk for malignant transformation (Russo 
et  al. 1982). While we observed an inverse association 










 Premenopausal 1124 (74) 1676 (76) 1.0 (ref.) 1.0 (ref.)
 Postmenopausal/<45 years 195 (13) 282 (13) 1.10 (0.88, 1.38) 1.03 (0.81, 1.32)
 Postmenopausal/≥45 years 194 (13) 240 (11) 1.27 (0.98, 1.64) 1.19 (0.91, 1.57)
a Including offset for countermatching
b Adjusted for age at first diagnosis, histology at first diagnosis, family history, stage at first diagnosis, chemotherapy/hormonal treatment for first diagnosis, use of 
postmenopausal hormone therapy up to first diagnosis, age at menarche, age at menopause and parity, with offset for countermatching
c Among parous women only, additionally mutually adjusted for age at first FTP, number of FTP, breast-feeding
d Ptrend calculated by modeling category medians continuously
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Table 3 Multivariable-adjusted risk ratios (RR) and 95 % confidence intervals (95 % CI) for associations of reproductive 
risk factors and contralateral breast cancer (CBC), by estrogen receptor (ER) status of first breast cancer
ER-positive first tumors ER-negative first tumors Pheterogeneity








Age at menarche (years)
 ≤11 160 (20) 269 (21) 1.0 (ref.) 99 (21) 106 (19) 1.0 (ref.)
 12 226 (28) 301 (24) 1.25 (0.92, 1.70) 131 (28) 134 (24) 1.07 (0.70, 1.65)
 13 210 (26) 325 (26) 0.94 (0.69, 1.28) 121 (26) 151 (27) 1.04 (0.68, 1.59)
 ≥14 199 (25) 358 (29) 0.93 (0.68, 1.28) 113 (24) 165 (29) 0.70 (0.45, 1.07)
 Pbtrend 0.27 0.09 0.40
Full-term pregnancies at first diagnosis
 None 173 (22) 248 (20) 1.0 (ref.) 95 (20) 98 (17) 1.0 (ref.)
 ≥1 623 (78) 1004 (80) 0.93 (0.73, 1.19) 371 (79) 462 (82) 0.95 (0.65, 1.39) 0.93
Full-term pregnancies between first diagnosis and reference date
 Parous at first diagnosis, 
no interval pregnancy
620 (78) 990 (79) 1.0 (ref.) 361 (77) 455 (81) 1.0 (ref.)
 Nulliparous at reference 
date
173 (22) 248 (20) 0.97 (0.72, 1.30) 95 (20) 98 (17) 1.00 (0.66, 1.51)
 Full-term pregnancy 
between first diagno-
sis and reference date
3 (0) 14 (1) 0.21 (0.04, 1.16) 10 (2) 7 (1) 1.88 (0.57, 6.18) 0.07
Number of full-term pregnancies at first diagnosisc
 1 144 (23) 198 (20) 1.0 (ref.) 72 (19) 100 (22) 1.0 (ref.)
 2 289 (46) 467 (47) 1.05 (0.73, 1.51) 182 (49) 213 (46) 0.97 (0.60, 1.57)
 3 134 (22) 211 (21) 0.97 (0.64, 1.47) 82 (22) 91 (20) 0.98 (0.56, 1.71)
 ≥4 56 (9) 128 (13) 0.52 (0.30, 0.90) 35 (9) 58 (13) 0.60 (0.30, 1.19)
 Pbtrend 0.02 0.14 0.95
Age at first full-term pregnancy at reference date (years)c
 <20 78 (13) 153 (15) 1.0 (ref.) 70 (19) 68 (15) 1.0 (ref.)
 20–24 211 (34) 359 (36) 1.14 (0.74, 1.76) 147 (40) 170 (37) 1.00 (0.59, 1.68)
 25–29 197 (32) 315 (31) 1.21 (0.77, 1.89) 91 (25) 132 (29) 0.56 (0.32, 0.99)
 ≥30 137 (22) 177 (18) 1.43 (0.87, 2.36) 63 (17) 92 (20) 0.66 (0.35, 1.27)
 Pbtrend 0.18 0.03 0.03
Breastfeeding at reference date (months)c
 Never 180 (29) 308 (31) 1.0 (ref.) 136 (37) 150 (32) 1.0 (ref.)
 Ever 443 (71) 696 (69) 1.09 (0.81, 1.47) 233 (63) 311 (67) 0.69 (0.48, 1.00) 0.05
 ≤6 224 (36) 350 (35) 1.06 (0.76, 1.48) 111 (30) 172 (37) 0.65 (0.42, 1.00)
 7–12 82 (13) 148 (15) 1.03 (0.66, 1.61) 66 (18) 53 (11) 0.95 (0.55, 1.66)
 13–24 86 (14) 132 (13) 1.09 (0.69, 1.72) 35 (9) 50 (11) 0.83 (0.43, 1.62)
 ≥25 51 (8) 66 (7) 1.53 (0.87, 2.72) 21 (6) 36 (8) 0.48 (0.22, 1.02)
 Pbtrend 0.19 0.15 0.07
Time since last full-term pregnancy, at reference date (years)c, d
 <15 104 (17) 250 (23) 0.87 (0.58, 1.32) 88 (24) 122 (26) 0.95 (0.59, 1.53)
 15–<20 104 (17) 165 (15) 1.06 (0.74, 1.54) 60 (16) 70 (15) 1.04 (0.65, 1.68)
 ≥20 415 (67) 654 (61) 1.0 (ref.) 223 (60) 270 (58) 1.0 (ref.)
 Pbtrend 0.65 0.74 0.99
Time between menarche and first full-term pregnancy at reference date (years)c
 <10 191 (31) 358 (36) 1.0 (ref.) 141 (38) 156 (34) 1.0 (ref.)
 10–14 217 (35) 352 (35) 1.29 (0.93, 1.80) 128 (35) 164 (36) 0.88 (0.58, 1.34)
 15–19 131 (21) 192 (19) 1.38 (0.94, 2.05) 65 (18) 87 (19) 0.86 (0.51, 1.45)
 ≥20 83 (13) 101 (10) 1.47 (0.93, 2.33) 35 (9) 50 (11) 0.58 (0.29, 1.17)
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was not associated with risk. In contrast, we observed 
that CBC risk was suggestively elevated among women 
with long intervals between menarche and first FTP. It is 
possible that this interval has greater biologic relevance 
to breast cancer than age at first FTP alone, as it may 
more accurately reflect the period during which rapidly 
expanding, undifferentiated breast epithelium is most 
vulnerable to carcinogenesis (Pike et  al. 1983; Li et  al. 
2008). Age at menarche itself was also inversely associ-
ated with CBC risk, consistent with findings for primary 
breast tumors (Collaborative Group on Hormonal Fac-
tors in Breast Cancer 2012).
To date, ours is the first analysis to examine associa-
tions between reproductive factors and CBC risk accord-
ing to ER status of the first primary tumor. We observed 
that a history of breast-feeding appeared to reduce risk of 
CBC among women diagnosed with an ER-negative first 
breast cancer; women who breast-fed for 25  months or 
more had the greatest reduction in risk, though no sig-
nificant trend was observed. Women with ER-negative 
first tumors have higher CBC risk (Saltzman et al. 2012; 
Kurian et  al. 2009) and do not benefit from treatment 
with tamoxifen (Early Breast Cancer Trialists’ Collabo-
rative Group et  al. 2011). Breast-feeding has consist-
ently been associated with reduced risk of first primary 
ER-negative subtypes (Gaudet et al. 2011; Millikan et al. 
2008; Tamimi et  al. 2012; Palmer 2014). Some evidence 
has suggested that breast-feeding may reduce breast 
cancer risk even among women at highest risk of breast 
cancer, specifically BRCA1 mutation carriers (Jernstrom 
et al. 2004; Kotsopoulos et al. 2012), who tend to develop 
ER-negative tumors (Foulkes et  al. 2004) and have ele-
vated CBC risk (Graeser et al. 2009; Malone et al. 2010). 
In the present study, we lacked BRCA1 and BRCA2 muta-
tion status for women sampled in WECARE II; however, 
our results suggest that breast-feeding may mitigate some 
of the increased risk of CBC associated with having an 
ER-negative first primary tumor.
We additionally observed evidence of heterogeneity in 
the associations of age at first FTP with CBC risk by ER 
status of the first tumor. Older age at first FTP was sug-
gestively associated with increased risk among women 
with ER-positive first tumors, but inversely associated 
with CBC risk among women with ER-negative first 
tumors. These findings are consistent with a recent review 
(Anderson et  al. 2014), which indicated that late age at 
first pregnancy was positively associated with risk of hor-
mone receptor-positive first primary tumors in 15 out of 
22 published analyses, while associations with hormone 
receptor-negative tumors reported from 13 analyses were 
null or inverse. Though no statistically significant hetero-
geneity was observed, a long interval between menarche 
and first FTP was associated with an increased CBC risk 
among women with ER-positive first breast cancers only, 
consistent with findings from some previous analyses of 
first primaries (Ritte et al. 2013; Li et al. 2008; Chung et al. 
2013; Ambrosone 2015). Here, we did not observe het-
erogeneity by ER status for the association between age 
at menarche and CBC risk, though a suggestive inverse 
association was observed for ER-negative tumors only. 
Instead, our results suggest that the effects of menarcheal 
age on CBC risk may be modified by the hormonal milieu, 
with stronger inverse associations observed for women 
who were postmenopausal at first diagnosis, regardless of 
ER status. However, in a large meta-analysis (Collabora-
tive Group on Hormonal Factors in Breast Cancer 2012), 
younger age at menarche was associated with risk of both 
pre- and postmenopausal primary breast cancer, with a 
weakening of the effect among postmenopausal women 
observed with increasing age at diagnosis.
Some limitations of our study must be acknowledged. 
Although our study benefited from a large sample size, 
Table 3 continued
ER-positive first tumors ER-negative first tumors Pheterogeneity








 Pbtrend 0.06 0.15 0.10
Menopausal status/age at menopause at 2 years before first diagnosis
 Premenopausal 583 (73) 932 (74) 1.0 (ref.) 348 (75) 345 (78) 1.0 (ref.)
 Postmenopau-
sal/<45 years
99 (12) 164 (13) 1.00 (0.72, 1.40) 65 (14) 65 (12) 1.44 (0.92, 2.26)
 Postmenopau-
sal/≥45 years
113 (14) 149 (12) 1.39 (0.98, 1.97) 50 (11) 59 (11) 1.03 (0.62, 1.71) 0.19
a Adjusted for age at first diagnosis, histology at first diagnosis, family history, stage at first diagnosis, chemotherapy/hormonal treatment for first diagnosis, use of 
postmenopausal hormone therapy up to first diagnosis, age at menarche, age at menopause and parity, with offset for countermatching
b Among parous women only, additionally mutually adjusted for age at first FTP, number of FTP, breastfeeding
c Ptrend calculated by modeling category medians continuously
d Categories collapsed due to small numbers
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only 44 FTPs occurred after first diagnosis, and we there-
fore had limited power to examine whether pregnancy 
or breast-feeding following a first primary breast cancer 
diagnosis is associated with CBC risk. Small numbers 
for some subgroups (i.e., ER-negative tumors/postmeno-
pausal status) may have also limited our ability to detect 
Table 4 Multivariable-adjusted risk ratios (RR) and 95 % confidence intervals (95 % CI) for associations of reproductive 
risk factors and contralateral breast cancer (CBC), by estrogen receptor (ER) status of first breast cancer and menopausal 
status 2 years prior to first breast cancer diagnosis
a Adjusted for age at first diagnosis, histology at first diagnosis, family history, stage at first diagnosis, chemotherapy/hormonal treatment for first diagnosis, use of 
postmenopausal hormone therapy up to first diagnosis, age at menarche, age at menopause and parity, with offset for countermatching
b Among parous women only, additionally mutually adjusted for age at first FTP, number of FTP, breastfeeding
c Ptrend calculated by modeling category medians continuously. Estimates for time since last full-term pregnancy and interval pregnancies not shown due to small 
numbers
ER-positive first tumors ER-negative first tumors Pheterogeneity

















Age at menarche (years)
 ≤11 94/205 1.0 (ref.) 65/63 1.0 (ref.) 72/83 1.0 (ref.) 27/23 1.0 (ref.)
 12 166/219 1.74 (1.20, 2.53) 60/81 0.63 (0.36, 1.13) 95/108 0.96 (0.58, 1.58) 35/25 1.75 (0.71, 4.33)
 13 168/236 1.56 (1.08, 2.27) 41/85 0.29 (0.16, 0.52) 97/121 1.12 (0.69, 1.81) 23/30 0.75 (0.30, 1.86)
 ≥14 153/271 1.33 (0.91, 1.93) 46/85 0.45 (0.25, 0.81) 81/120 0.79 (0.48, 1.32) 30/44 0.45 (0.20, 1.04)
 Pbtrend 0.33 0.001 0.62 0.01 0.0001
Full-term pregnancies at first diagnosis
 None 133/187 1.0 (ref.) 40/60 1.0 (ref.) 76/82 1.0 (ref.) 18/16 1.0 (ref.)
 ≥1 449/744 0.87 (0.65, 1.15) 172/253 1.22 (0.74, 2.00) 272/353 0.97 (0.63, 1.48) 96/107 0.84 (0.36, 1.95) 0.71
Number of full-term pregnancies at first diagnosisc
 1 111/146 1.0 (ref.) 32/52 1.0 (ref.) 56/78 1.0 (ref.) 15/21 1.0 (ref.)
 2 221/369 0.99 (0.65, 1.49) 67/93 1.53 (0.74, 3.14) 140/175 1.02 (0.60, 1.74) 41/37 1.41 (0.41, 4.93)
 3 89/156 1.00 (0.62, 1.61) 45/53 1.22 (0.54, 2.75) 56/63 1.03 (0.53, 1.98) 25/28 1.57 (0.56, 4.42)
 ≥4 28/73 0.41 (0.20, 0.82) 28/55 0.81 (0.34, 1.94) 20/37 0.64 (0.28, 1.44) 15/21 1.43 (0.44, 4.68)
 Pbtrend 0.03 0.28 0.28 0.52 0.98
Age at first full-term pregnancy at reference date (years)c
 <20 46/92 1.0 (ref.) 32/60 1.0 (ref.) 41/44 1.0 (ref.) 29/24 1.0 (ref.)
 20–24 136/252 1.12 (0.63, 1.96) 75/105 1.25 (0.64, 2.47) 104/117 1.14 (0.58, 2.21) 42/53 0.76 (0.32, 1.78)
 25–29 152/246 1.24 (0.70, 2.18) 44/68 1.38 (0.65, 2.95) 72/108 0.61 (0.31, 1.22) 18/23 0.51 (0.18, 1.47)
 ≥30 115/154 1.35 (0.74, 2.47) 21/20 2.30 (0.84, 6.25) 55/84 0.64 (0.30, 1.41) 7/7 0.87 (0.19, 3.92)
 Pbtrend 0.28 0.13 0.03 0.40 0.17
Breastfeeding at reference date (months)c
 Never 111/198 1.0 (ref.) 69/106 1.0 (ref.) 98/106 1.0 (ref.) 38/43 1.0 (ref.)
 Ever 338/546 1.26 (0.87, 1.81) 103/147 0.90 (0.52, 1.54) 172/246 0.62 (0.40, 0.96) 58/64 0.72 (0.34, 1.51) 0.07
 ≤6 164/259 1.31 (0.87, 1.97) 58/89 0.74 (0.40, 1.36) 75/127 0.59 (0.35, 1.00) 34/44 0.59 (0.25, 1.38)
 7–12 63/118 1.10 (0.65, 1.87) 19/29 1.13 (0.48, 2.63) 51/43 0.94 (0.49, 1.79) 14/10 0.83 (0.26, 2.67)
 13–24 72/112 1.24 (0.74, 2.08) 14/20 1.33 (0.41, 4.35) 28/46 0.71 (0.35, 1.48) 7/4 1.59 (0.23, 10.8)
 ≥25 39/57 1.78 (0.93, 3.38) 12/9 1.50 (0.37, 6.04) 18/30 0.37 (0.16, 0.86) 3/6 1.23 (0.17, 9.17)
 Pbtrend 0.20 0.28 0.06 0.71 0.19
Time between menarche and first full-term pregnancy at reference date (years)c
 <10 119/237 1.0 (ref.) 72/118 1.0 (ref.) 90/102 1.0 (ref.) 50/54 1.0 (ref.)
 10–14 161/260 1.26 (0.85, 1.870 56/91 1.52 (0.82, 2.81) 96/121 0.86 (0.51, 1.44) 31/42 0.91 (0.41, 1.99)
 15–19 103/160 1.32 (0.84, 2.06) 27/31 1.85 (0.84, 4.04) 56/81 0.72 (0.40, 1.29) 9/6 1.74 (0.39, 7.81)
 ≥20 65/86 1.25 (0.74, 2.08) 17/13 3.70 (1.27, 10.9) 28/46 0.46 (0.21, 1.01) 6/3 1.42 (0.26, 7.93)
 Pbtrend 0.30 0.009 0.05 0.59 0.17
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heterogeneity in some stratified analyses. In order to 
qualify for inclusion into our study, participants had to be 
alive at time of recruitment; we cannot rule out the possi-
bility that women who died before this time had different 
distributions of reproductive factors than those who were 
alive. In order to limit the potential for resulting survival 
bias, we restricted eligibility to women whose cancer had 
not spread beyond regional lymph nodes, and matched 
cases and controls on both age and year categories of first 
diagnosis.
Our results provide further evidence that some repro-
ductive factors known to be associated with first primary 
breast cancers are additionally associated with CBC risk. 
Specifically, we confirmed our previous findings from 
the WECARE I study population, which indicated that 
older age at menarche and increasing parity appear pro-
tective for CBC. While not associated with overall CBC 
risk, increasing age at first FTP appeared inversely asso-
ciated with risk among women with ER-negative first 
primaries. Additionally, while we found no association 
between breast-feeding and CBC risk our previous study, 
here, we report an inverse association that appears lim-
ited to women with ER-negative first tumors, who are at 
a higher risk of CBC, particularly ER-negative subtypes 
[Sisti et al., submitted]. These results add to others which 
suggest that breast-feeding may play a protective role in 
the etiology of ER-negative breast cancers, and provide 
the first evidence that this protective effect persists for 
second breast tumors. Further studies are needed to clar-
ify these associations.
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